Enhancement of Antitumor Immunity by CTLA-4 Blockade
1996; American Association for the Advancement of Science; Volume: 271; Issue: 5256 Linguagem: Inglês
10.1126/science.271.5256.1734
ISSN1095-9203
AutoresDana R. Leach, Matthew F. Krummel, James P. Allison,
Tópico(s)Immune Cell Function and Interaction
ResumoOne reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.
Referência(s)